Drug resistant tuberculosis in adults and its treatment

Journal of the Royal College of Physicians of London

Volumn 32, Issue 4, 1998, Pages 314-318

  Drobniewski, Francis ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; BENZOXAZINE DERIVATIVE; CAPREOMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; MACROLIDE; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

DRUG DELIVERY SYSTEM; HUMAN; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MYCOBACTERIUM TUBERCULOSIS; ORAL DRUG ADMINISTRATION; SHORT SURVEY; SIDE EFFECT; TUBERCULOSIS;

ADULT; ANTITUBERCULAR AGENTS; HUMANS; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 0031706324     PISSN: 00358819     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (18)

1. Drobniewski F, Pablos Mendez A, Raviglione MC. Epidemiology of tuberculosis in the world. Semin Respir Crit Care Med 1997;18:419-29.
2. Raviglione MC, Dye C, Schmidt S, Kochi A. The WHO Global Surveillance and Monitoring Project. Assessment of worldwide tuberculosis control. Lancet 1997;350:624-9.
3. Drobniewski FA. Is death inevitable with multiresistant TB plus HIV infection? Lancet 1997;349:71-2.
4. World Health Organisation/ International Union Against Tuberculosis and Lung Disease. Anti-tuberculosis drug resistance in the world. Geneva, Switzerland: WHO, 1997.
5. Bennett DE, Brady AR, Herbert J, Drobniewski F, et al. Drug resistant TB in England and Wales 1993-1995. Thorax 1996;51(Suppl 3):S32.
6. O'Brien RJ. Clinical studies of new rifamycins for the treatment and prevention of tuberculosis. Int J Tuberculosis Lung Dis 1997;1:S11.
7. Hirata T, Saito H, Tomioka H, Sato K, et al. In vitro and in vivo activities of the benzoxazinorifamycin KRM 1648 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39:2295-303.
8. Luna Herrera J, Reddy VM, Daneluzzi D, Gangadharam PR. Antituberculosis activity of clarithromycin. Antimicrob Agents Chemother 1995;39:2692-5.
9. Gangadharam PR, Ashtekar DR, Farthi DC, Wise DL. Sustained release of isoniazid from a single implant of biodegradable polymer. Tubercle 1991; 72:115-22.
10. Corlan E, Marcia C, Macavei C, Stanford JL, Stanford CA. Immunotherapy with Mycobacterium vaccae in the treatment of tuberculosis in Romania. Respir Med 1997;91:13-9.
11. Durman P. Stanford Rook's 'miracle cure' for TB fails. The Times (London), 1 October 1997.
12. Flynn JL, Chan J, Triebold KJ, Dalton DK, et al. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J Exp Med 1993; 178:2249-54.
13. Newport MJ, Huxley CM, Huston S, Hawrylowicz CM, et al. A mutation in the interferon gamma receptor gene and susceptibility to mycobacterial infection. N Engl J Med 1996;335:1941-9.
14. Holland SM, Eisenstein EM, Kuhns DB, Turner ML, et al. Treatment of refractory disseminated non tuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 1994;330:1348-55.
15. Condos R, Rom WN, Schluger NW. Treatment of multidrug resistance pulmonary TB with interferon gamma via aerosol. Lancet 1997;349:1513-5.
16. Tramontana JM, Utaipat U, Molloy A, Akrasewi P, et al. Thalidomide treatment reduces tumor factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-97.
17. Flynn JL, Goldstein MM, Triebold KJ, Sypek J, et al. IL-12 increases resistance of BALB/c to Mycobacterium tuberculosis infection. J Immunol 1995;155: 2515-24.
18. Cooper AM, Roberts AD, Rhoades ER, Callahan JE, et al. The role of interleukin 12 in acquired immunity to Mycobacterium tuberculosis infection. Immunology 1995;84:423-32.